Medical News Today -
3 Dec 2013 12:00
A new clinical trial for breast cancer, published in The Lancet, shows that a single fraction of targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM® at time of lumpectomy is non-inferior to traditional external beam radiation (EBRT) delivered over three to six weeks after breast conserving surgery, for a select group of patients."The most important benefit of TARGIT for a woman with breast cancer is that it allows her to complete her entire local treatment at the t...
Share this Article